Venture
Ventus Therapeutics U.S., Inc.
Latest Form D 2022-02-11- CIK 1794785
- State MA
- Biotechnology
- 3 Form D offerings since 2020-05-07
- Total sold
- $187M
- across 3 offerings
- Rounds
- 3
- Form D offerings since 2020-05-07
- Latest round
- $70M
- 2022-02-11 · 021-433406
- Investors
- 13
- on the latest round
Connected
named in its Form D filingsOfferings · since 2020-05-073 Form D offeringsExemptions506(b)People · Item 3Marcelo Bigal + 11 moreInvestors · dashboardInferred investors
Ventus Therapeutics U.S., Inc.CIK 1794785
Round timeline
amount sold · by first filed2022-02-11 · $70M
- 2020-05-07$16.8M021-366465
- 2021-04-14$100M021-395752
- 2022-02-11$70M021-433406
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($100M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-433406 | First filed2022-02-11 | Latest2022-02-11 | Sought$140M | Sold$70M | Investors13 | Exemptions506(b) |
| 021-395752 | First filed2021-04-14 | Latest2021-04-14 | Sought$100M | Sold$100M | Investors17 | Exemptions506(b) |
| 021-366465 | First filed2020-05-07 | Latest2020-05-07 | Sought$60.1M | Sold$16.8M | Investors4 | Exemptions506(b) |
Who backs Ventus Therapeutics U.S., Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2022-02-11
| Name | Relationship |
|---|---|
| Marcelo Bigal | RelationshipExecutive Officer, Director |
| Jerel Davis | RelationshipDirector |
| Brendan Bulik-Sullivan | RelationshipDirector |
| Daniel Koerwer | RelationshipExecutive Officer |
| Zachary McNealy | RelationshipExecutive Officer |
| Josh Resnick | RelationshipDirector |
| Steven James | RelationshipDirector |
| Michael Crackower | RelationshipExecutive Officer |
| Jane Pritchett Henderson | RelationshipDirector |
| Dolca Thomas | RelationshipDirector |
| Markus Warmuth | RelationshipDirector |
| John Cassidy | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2020-05-07
- Latest filing
- 2022-02-11
Who backs Ventus Therapeutics U.S., Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗